Compare · GLP-1 agonist
CagriSema vs Mazdutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | Mazdutide | |
|---|---|---|
| Evidence | 9/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | A GLP-1/glucagon dual agonist approved in China for weight loss and diabetes, with genuine RCT evidence that is still sponsor-funded and single-country. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the pipeline of new obesity drugs. It's also a good example of why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It's a once-weekly shot that packs two peptides into a single…
Mazdutide
Mazdutide is an injectable drug for weight loss and type 2 diabetes that switches on two of the body's metabolic hormone receptors at the same time. Most of the buzzy GLP-1 compounds are still stuck at the press-release stage, but mazdutide is further along: it has a full Phase 3 trial published in…